Journal of Immunotherapy and Precision Oncology最新文献

{"title":"Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer.","authors":"Cláudia Vieira,&nbsp;Andreia Borges,&nbsp;Filipa F Pereira,&nbsp;Pedro Antunes,&nbsp;Patrícia Redondo,&nbsp;Luís Antunes,&nbsp;José M Lopes,&nbsp;Francisco R Gonçalves,&nbsp;Marina Borges,&nbsp;Maria J Bento","doi":"10.36401/JIPO-22-12","DOIUrl":"https://doi.org/10.36401/JIPO-22-12","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to assess safety and effectiveness of pertuzumab in combination with trastuzumab and docetaxel in the neoadjuvant treatment (NeoT) of HER2-positive breast cancer.</p><p><strong>Methods: </strong>Two consecutive retrospective cohorts (<i>n</i> = 94, 2012-2015 and 2015-2017) of adult women with HER2-positive breast cancer, receiving NeoT at the breast clinic in Portugal (IPO-Porto), were followed. All patients had surgery and received trastuzumab as adjuvant therapy. The 2012-2015 cohort received doxorubicin, cyclophosphamide, docetaxel plus trastuzumab, whereas the 2015-2017 cohort was treated with the same protocol plus pertuzumab.</p><p><strong>Results: </strong>The 2012-2015 cohort was older (median 53 years), with locally advanced tumors (48.1%), mostly hormone receptor positive (59.3%). The 2015-2017 cohort was younger (median 43 years) with 60% operable tumors. Pathologic complete response (pCR) improved in the second cohort, while maintaining a good safety profile and tolerability. Clinical staging (<i>p</i> = 0.001) and hormone receptor (<i>p</i> = 0.003) were significant predictors of pCR, but not treatment regimen (<i>p</i> = 0.304).</p><p><strong>Conclusion: </strong>Further research with larger samples and longer follow-up is needed to understand the clinical differences. Clinical effectiveness of treatment should also be measured through overall and progression-free survival.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/d7/i2590-017X-6-1-1.PMC9888519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10681237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.","authors":"Ji Son,&nbsp;Heather Y Lin,&nbsp;Siqing Fu,&nbsp;Amadeo B Biter,&nbsp;Ecaterina E Dumbrava,&nbsp;Daniel D Karp,&nbsp;Aung Naing,&nbsp;Shubham Pant,&nbsp;Sarina A Piha-Paul,&nbsp;Jordi Rodon,&nbsp;Vivek Subbiah,&nbsp;Apostolia M Tsimberidou,&nbsp;Timothy A Yap,&nbsp;Michael M Frumovitz,&nbsp;Amir A Jazaeri,&nbsp;Pedro T Ramirez,&nbsp;Shannon N Westin,&nbsp;Ying Yuan,&nbsp;Funda Meric-Bernstam,&nbsp;David S Hong","doi":"10.36401/JIPO-22-23","DOIUrl":"https://doi.org/10.36401/JIPO-22-23","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials.</p><p><strong>Methods: </strong>Patients with cervical cancer who received at least one dose of a phase I investigational agent at our institution between 2014 and 2022 were included. The log-rank test was used to analyze differences in progression-free survival (PFS) and overall survival (OS), and multivariable regression analysis was performed.</p><p><strong>Results: </strong>We included 65 patients with a median age of 41 years (range, 20-74), 3 prior therapies (range, 1-7), and 67.7% squamous carcinoma. The rate of distant metastasis at trial entry was 84.6%. The most common molecular alterations included PIK3CA (46.5%), PD-L1+ (46.2%), EPH (30.0%), and CREBBP (23.1%); 23.1% had received a prior checkpoint inhibitor. Phase I trials were for immunotherapy (58.5%) or targeted therapy (41.5%). The rate of biomarker matching was 21.5%. For all patients, median PFS was 3.6 months (95% CI, 2.0-5.2) and OS was 9.3 months (95% CI, 7.0-10.6). Factors at study entry associated with worse survival were presence of bone metastasis (PFS 1.6 vs 4.4 months: hazard ratio [HR], 2.8; <i>p</i> = 0.001; OS 3.8 vs 10.0 months: HR, 3.9; <i>p</i> < 0.0001) and absolute lymphocyte count below 1000/μL (PFS 1.8 vs 5.2 months: HR, 2.9; <i>p</i> = 0.0004; OS 7.0 vs 10.6 months: HR, 3.2; <i>p</i> = 0.0009). Factors associated only with worse OS were absolute neutrophil count above 4700/μL, hemoglobin below 10.5 g/dL, and smoking status. Grade 3+ treatment-related adverse events were seen in 16.9% of cases.</p><p><strong>Conclusion: </strong>Bone metastasis and absolute lymphocyte count below normal range at phase I study entry portend poor survival in patients with recurrent or metastatic cervical cancer.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 1","pages":"10-18"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/4f/i2590-017X-6-1-10.PMC9888522.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10681235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.","authors":"Samer A Srour,&nbsp;Serkan Akin","doi":"10.36401/JIPO-22-7","DOIUrl":"https://doi.org/10.36401/JIPO-22-7","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy is the new standard treatment for various indications in patients with advanced hematologic malignancies. Despite the several preclinical and early phase clinical trials, the overall clinical experience has been disappointing when applying this innovative therapy in solid tumors. The failure of CAR T-cell therapy and its limited antitumor activity in solid tumors have been attributed to several mechanisms, including tumor antigen heterogeneity, the hostile tumor microenvironment and poor trafficking of CAR T cells into tumor sites, and the unacceptable toxicities in some settings, among others. However, remarkable improvements have been made in understanding many of these failure mechanisms for which several emerging novel approaches are being applied to overcome these challenges. In this review, after a brief historic background for immunotherapy in solid tumors, we highlight the recent developments achieved in CAR T-cell designs, summarize completed clinical trials, and discuss current challenges facing CAR T-cell therapy and the suggested strategies to overcome these barriers.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 1","pages":"19-30"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/d0/i2590-017X-6-1-19.PMC9888521.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10674937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus.","authors":"Viraj A Master,&nbsp;Benjamin N Schmeusser,&nbsp;Adeboye O Osunkoya,&nbsp;Arnold R Palacios,&nbsp;Eric Midenberg,&nbsp;Lauren Yantorni,&nbsp;Kenneth Ogan,&nbsp;Mehmet A Bilen","doi":"10.36401/JIPO-22-16","DOIUrl":"https://doi.org/10.36401/JIPO-22-16","url":null,"abstract":"<p><p>Renal cell carcinoma with level IV tumor thrombus is a condition necessitating aggressive surgical management. Many solid organ malignancies often benefit from neoadjuvant treatments for tumor debulking and improvement of surgical outcomes. However, neoadjuvant treatments for renal cell carcinoma have been limited by its resistance to traditional chemotherapy and radiation. Emerging treatment modalities, such as immunotherapies, are exciting new options that may be therapeutically effective. The combination of nivolumab and ipilimumab has exhibited success in managing metastatic renal cell carcinoma. Limited data exist for its use in nonmetastatic renal cell carcinoma with tumor thrombus. This case illustrates the use of nivolumab and ipilimumab combination therapy in delaying tumor growth, producing observable tumor thrombus histologic and radiologic treatment changes, and, most importantly, facilitating a less invasive surgical approach of a level IV renal cell carcinoma tumor thrombus.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 1","pages":"50-55"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/85/i2590-017X-6-1-50.PMC9888517.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10674935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.","authors":"Anagha Deshpande,&nbsp;Javier Munoz,&nbsp;Katalin Kelemen,&nbsp;Vrushali Dabak,&nbsp;Amr Hanbali,&nbsp;Razelle Kurzrock","doi":"10.36401/JIPO-22-22","DOIUrl":"https://doi.org/10.36401/JIPO-22-22","url":null,"abstract":"<p><p>Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 1","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/da/i2590-017X-6-1-56.PMC9888520.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10681240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive risk factor analysis of oral submucous fibrosis among gond tribes of central India: A cross-sectional study","authors":"Satyaprakash Nigam, Rupal Saxena, Sabhrant Singh, Ruchi Jain, Shaji Thomas","doi":"10.4103/jpo.jpo_14_23","DOIUrl":"https://doi.org/10.4103/jpo.jpo_14_23","url":null,"abstract":"Introduction: Oral submucous fibrosis (OSMF) is a potentially malignant disorder characterized by fibrotic changes in the oral mucosa. It is a significant public health concern, particularly among certain ethnic populations. The Gond tribes of Central India represent one such population, and the prevalence and risk factors associated with OSMF among them remain largely unexplored. This study aims to conduct a predictive risk factor analysis to identify the factors associated with OSMF among the Gond tribes and provide insights into the etiology and pathogenesis of the disease within this specific population. Materials and Methods: A cross-sectional study was conducted among the Gond tribal population of Central India. A total of 800 participants were included in the study. Oral examinations were conducted by trained researchers to assess the presence of OSMF and other oral health conditions. Demographic and socioeconomic data were collected, including age, gender, education level, occupation, and household income. Lifestyle factors such as tobacco and betel nut chewing, alcohol consumption, and oral hygiene practices were assessed through structured questionnaires. Dietary patterns and nutritional status were evaluated, and oral health-related factors such as dental caries, periodontal health, and other oral lesions were examined. Multivariate analysis was performed to identify independent risk factors associated with OSMF among the Gond tribes. Results: The prevalence of OSMF among the Gond tribes was 12.5%. Demographic analysis revealed a balanced representation of genders, with a range of age groups included. Lifestyle factors such as tobacco and betel nut chewing were prevalent among the Gond tribes, with a significant proportion of participants reporting regular use of these substances. Poor oral hygiene practices and undernutrition were also identified as risk factors. Dietary patterns showed a high consumption of carbohydrate-rich foods and a relatively low intake of fruits and vegetables in addition to OSMF. Conclusion: This study provides valuable insights into the prevalence and risk factors associated with OSMF among the Gond tribes of Central India. The findings highlight the need for targeted interventions addressing tobacco and betel nut chewing, poor oral hygiene practices, advanced age, low education level, and undernutrition within this population. Comprehensive oral health promotion programs, including tobacco cessation initiatives, oral hygiene education, nutritional interventions, and improved access to dental care, are crucial for reducing the prevalence of OSMF and improving oral health outcomes among the Gond tribes. Future research should focus on longitudinal studies to further elucidate the causal relationships and long-term impact of these risk factors on the development and progression of OSMF within the Gond tribal population.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"123 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135400721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomically driven NUTM1-NSD3 carcinoma of the lung: Opportunity for chemotherapy response","authors":"AmritKaur Kaler, Sheereen Fatima, ImranNisar Shaikh","doi":"10.4103/jpo.jpo_9_23","DOIUrl":"https://doi.org/10.4103/jpo.jpo_9_23","url":null,"abstract":"Nuclear protein in testis (NUT) carcinoma is a rare, genetically-driven carcinoma defined by NUTM1 gene rearrangements. It frequently presents as an aggressive, poorly differentiated squamous cell carcinoma of the midline. NUT carcinoma originating in the lung is extremely uncommon. We present a unique case of a 23-year-old female diagnosed mucoepidermoid carcinoma of the lung found to harbor a rare NSD3-NUTM1 gene fusion on targeted sequencing. Despite multiple metastases at diagnosis, she exhibited dramatic response to first-line carboplatin and paclitaxel doublet chemotherapy. Interim PET-CT after three cycles showed near complete resolution of the left hilar mass and metastases. This response was sustained after six total cycles and continues after six months on maintenance chemotherapy. To our knowledge, this represents the first reported case of NUTM1-NSD3 fusion positive lung carcinoma displaying chemosensitivity, unlike the typically aggressive course of NUT cancers. Our case reveals the emerging molecular heterogeneity of these rare malignancies and suggests platinum doublets may be an effective treatment option warranting further study. Overall, it highlights the potential for precision diagnostics to uncover actionable targets and prognostic insights even in elusive cancers.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135401019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the psychosocial determinants of patients and caregivers seeking treatment at a tertiary cancer care center: A clinical study","authors":"Harsha Agarwal, Shalu Rana, Disha Mittal","doi":"10.4103/jpo.jpo_5_23","DOIUrl":"https://doi.org/10.4103/jpo.jpo_5_23","url":null,"abstract":"Objective: This clinical study aimed to evaluate the psychosocial determinants influencing patients and caregivers seeking treatment at a tertiary cancer care center. Methods: The study included 175 patients or caregivers (86 males and 88 females) who visited the cancer hospital for checkups or treatment. Data were collected using self-designed questionnaires. The questionnaire assessed psychological and psychosocial issues, including anxiety, sleep, appetite, pain, fatigue, distress, depression, financial issues, family issues, social support, occupational issues, sexual issues, patient satisfaction, mood and thought, and concerns about the future. Statistical analyses, such as independent t-tests, were conducted to compare the differences between demographic factors and psychological and psychosocial issues. Results: The findings revealed that males scored higher on psychological issues, while females scored higher on psychosocial issues. Caregivers reported higher scores on both psychological and psychosocial issues compared to patients. Married patients exhibited higher scores on anxiety, sleep, and appetite compared to unmarried patients. Moreover, individuals with a family history of cancer scored higher on psychological issues, while those without a family history of cancer scored higher on psychosocial issues. Conclusion: The study highlights the significance of addressing psychosocial determinants when patients or their caregivers visit a tertiary cancer care center. Understanding and addressing psychological and psychosocial factors can contribute to better support and treatment for cancer patients and their caregivers.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"157 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135400485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe respiratory depression in a beta-thalassemia patient: A case of furosemide-induced hypokalemia precipitated by morphine","authors":"SachinSuresh Jadhav, AbhijnaVithal Yergolkar, JyothiGoutham Kumar, Nishit Ojha, Priyank Tripathi, AmeyC Panchal","doi":"10.4103/jpo.jpo_7_23","DOIUrl":"https://doi.org/10.4103/jpo.jpo_7_23","url":null,"abstract":"This case report describes a rare occurrence of severe respiratory failure in a 4-year-old child with beta-thalassemia after the administration of Furosemide and morphine. The patient experienced hypokalemia (potassium levels - 2.69 mmol/L) following Furosemide administration, which worsened after morphine intake, leading to Type II respiratory failure. Immediate potassium correction and naloxone administration were initiated, but unfortunately, the patient succumbed to complications related to tracheostomy on D + 39. This report emphasizes the potential risks of Furosemide-induced hypokalemia and its interaction with morphine, resulting in severe respiratory depression.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135400508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of lynch syndrome in signet-ring cell carcinoma: A case report and review","authors":"AmritKaur Kaler, Sheereen Fatima, NandiniShyamali Bora, Shalaka Sawant, Varsha Balaji, P Kavyashree, Sandeep Goyle, Manoj Mulchandani","doi":"10.4103/jpo.jpo_11_23","DOIUrl":"https://doi.org/10.4103/jpo.jpo_11_23","url":null,"abstract":"Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer with distinct molecular features and aggressive behavior compared to adenocarcinoma. Most cases are diagnosed at an advanced stage with poor prognosis. SRCC is often associated with CpG island methylation phenotype (CIMP)-high, high (Methylation) BRAF mutations, but their prognostic role is unclear. We report a 57-year-old male with locally advanced sigmoid SRCC and germline Lynch syndrome (pathogenic MLH1 mutation). Despite the advanced stage, he has shown excellent response to adjuvant 5-fluorouracil chemotherapy, unlike typical SRCC outcomes. This case highlights the need to determine the prognostic and predictive significance of lynch syndrome in colorectal SRCC. Identifying patients with improved chemotherapy sensitivity in lynch Syndrome could treatment and improve survival in this rare histological subtype.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135401628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}